ReviewBlood research2026
High-risk features in adult patients with B-cell acute lymphoblastic leukemia: redefining risk in the era of targeted immunotherapy.
Review in Blood research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment landscape of adult B-cell acute lymphoblastic leukemia (B-ALL) has changed substantially with the introduction of targeted immunotherapeutic agents. Historically, high-risk disease was defined by clinical and cytogenetic features such as older age, elevated leukocyte count, and Philadelphia chromosome (Ph)-positive status. Advances in genomic profiling, together with the use of next-generation tyrosine kinase inhibitors, bispecific T-cell engagers, antibody-drug conjugates, and chimeric antigen receptor T-cell therapies, have altered both treatment outcomes and risk stratification. Outcomes for patients with Ph-positive B-ALL have improved markedly, particularly with ponatinib- and blinatumomab-based regimens, but several molecularly defined subgroups continue to have poor prognoses. These include IKZF1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.